Clinical and Experimental Sciences, Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
Hampshire Hospitals NHS Foundation Trust, Winchester, UK.
J Clin Pathol. 2018 Jun;71(6):554-558. doi: 10.1136/jclinpath-2017-204901. Epub 2018 Feb 15.
The opportunistic pathogen non-typeable (NTHi) plays an important role in many chronic respiratory diseases including otitis media, chronic rhinosinusitis, cystic fibrosis and chronic obstructive pulmonary disease. Biofilm formation has been implicated in NTHi colonisation, persistence of infection and recalcitrance towards antimicrobials. There is therefore a pressing need for the development of novel treatment strategies that are effective against NTHi biofilm-associated diseases. SurgihoneyRO is a honey-based product that has been bioengineered to enable the slow release of HO, a reactive oxygen species to which is susceptible. Treatment of established NTHi biofilms with SurgihoneyRO significantly reduced biofilm viability through enhanced HO production and was shown to be more effective than the conventional antibiotic co-amoxiclav.
机会性病原体非定型流感嗜血杆菌（NTHi）在许多慢性呼吸道疾病中起着重要作用，包括中耳炎、慢性鼻-鼻窦炎、囊性纤维化和慢性阻塞性肺疾病。生物膜的形成与 NTHi 的定植、感染的持续存在以及对抗微生物药物的耐药性有关。因此，迫切需要开发针对 NTHi 生物膜相关疾病的新型治疗策略。SurgihoneyRO 是一种基于蜂蜜的产品，经过生物工程处理后能够缓慢释放 HO，一种 易受其影响的活性氧。SurgihoneyRO 处理已建立的 NTHi 生物膜可显著提高 HO 的产生，从而降低生物膜的活性，并且比常规抗生素复方新诺明更有效。
